Topical Minoxidil Withdrawal and Discontinuation Syndrome: What to Expect When You Stop
At a glance
- Drug / minoxidil topical 2% and 5% (Rogaine and store brands), over the counter
- What stopping does / the labels say continued use is needed to keep regrowth, or hair loss begins again [1][2]
- Results while using / men's 5% solution label: results at 2 months, at least 4 months for some; women's 5% foam label: 3 months, up to 6 months [1][2]
- Unwanted facial and limb hair / disappeared from the face and arms 1 to 3 months after stopping 5% topical minoxidil in a 5-woman case series [3]
- Heart disease / listed as a precaution on the topical labels, with chest pain, rapid heartbeat, faintness and dizziness listed as reasons to stop use [1][2]
Is there such a thing as topical minoxidil withdrawal?
Withdrawal in the medical sense means a physical syndrome after a drug is stopped. The OTC labels list no such symptoms; what they describe is what happens to the hair when application ends [1][2].
What the labels say happens when you stop
The men's 5% solution and the women's 5% foam carry the same sentence: continued use is necessary to increase and keep hair regrowth, or hair loss will begin again [1][2]. The labels do not say how quickly hair loss returns.
The labels tie results to months of use rather than weeks. The men's 5% solution label, for twice-daily use of 1 mL, says results may occur at 2 months and some men may need at least 4 months; the women's 5% foam label, for half a capful once daily, says 3 months and some women may need at least 6 months [1][2].
Unwanted hair after stopping
In a case series of five women using 5% topical minoxidil, all five developed severe hypertrichosis of the face and limbs after 2 to 3 months of treatment. After minoxidil was discontinued, the hypertrichosis disappeared from the face and arms in 1 to 3 months and from the legs in 4 to 5 months; the authors hypothesized systemic absorption and a high sensitivity to minoxidil of the follicles in these areas [3].
Hypertrichosis was also more frequent with 5% than with 2% or placebo in the 48-week trial of 381 women, along with more itching and scalp irritation [5].
What the labels list as reasons to stop use
The labels say to stop use if chest pain, rapid heartbeat, faintness or dizziness occurs, if sudden unexplained weight gain occurs, if the hands or feet swell, if scalp irritation or redness occurs, if unwanted facial hair growth occurs, or if there is no hair regrowth after 4 months (men's 5% solution) or 6 months (women's 5% foam) [1][2]. Both labels also list heart disease as a precaution before use [1][2].
Frequently asked questions
Is minoxidil withdrawal real?
How long after stopping minoxidil does hair fall out?
Does the extra facial hair go away after stopping?
References
- U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
- U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
- Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol. 1997;136(1):118-20. Diffuse hypertrichosis during treatment with 5% topical minoxidil
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786. Minoxidil and its use in hair disorders: a review
- Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
- Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022;33(4):1896-1906. Minoxidil: a comprehensive review
- U.S. Food and Drug Administration. U.S. Food and Drug Administration
- Olsen EA, Sinclair R, Hordinsky M, Mesinkovska NA, Sadick N, Shapiro J, et al. Summation and recommendations for the safe and effective use of topical and oral minoxidil. J Am Acad Dermatol. 2025;93(2):457-465. Summation and recommendations for the safe and effective use of topical and oral minoxidil
- Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
- Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160(6):600-605. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial
- Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial. J Cosmet Dermatol. 2024;23(3):949-957. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
- Chen M, Weichert M, Guo W, Ruzic R, Briley J. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(3):554-555. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis